| What should medical practitioners know about the role of alternative medicines in cardiovascular disease management? | |
| | |
MedLine Citation:
|
PMID: 20398100 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Alternative medications as a term call up many different meanings, significance, and perceptions to various medical practitioners. Some are good; others are bad. A wide range of alternative medications with relevance or connection to cardiovascular (CV) disease have been considered. While many are worthless, others have definite benefit, and at least one, chelation therapy, is associated with definite harm, significant risk, no benefit, and enrichment of the practitioners who prescribe it. The issues concerning alternative therapies will likely never be studied with randomized clinical trials due to the lack of a profit motive on the part of pharmaceutical companies--only rarely do other institutions, such as the National Institutes of Health, support medicinal studies. Basic knowledge of alternative therapies is essential for the CV specialist and other practicing physicians and other practitioners, since at least a few of their patients will take these medications regardless of medical advice. The result is that a number of these alternative medications will then interact with conventional CV medications, many times unfavorably. |
| | |
Authors:
|
Thomas F Whayne |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cardiovascular therapeutics Volume: 28 ISSN: 1755-5922 ISO Abbreviation: Cardiovasc Ther Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-04-19 Completed Date: 2010-07-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101319630 Medline TA: Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 106-23 Citation Subset: IM |
Affiliation:
|
Gill Heart Institute, University of Kentucky, Lexington, KY, USA. twhayn0@uky.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Attitude of Health Personnel Cardiology* Cardiovascular Agents / adverse effects, therapeutic use* Cardiovascular Diseases / drug therapy, therapy* Complementary Therapies* / adverse effects Drug Interactions Health Knowledge, Attitudes, Practice Humans Physician's Practice Patterns Risk Assessment |
| Chemical | |
Reg. No./Substance:
|
0/Cardiovascular Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Insulin signaling: a possible pathogenesis of cardiac hypertrophy.
Next Document: Contemporary limbal stem cell transplantation - a review.